Dendreon (DNDN) and OncoGenex (OGXI) Could See Interest On JNJ's Cougar Biotech Deal
Dendreon Corp. (Nasdaq: DNDN) and OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) are seeing some interest this morning after news Johnson & Johnson (NYSE: JNJ) agreed to acquire Cougar Biotechnology, Inc. (Nasdaq: CGRB) for $1 billion, or $43 per share.
Speculators view these as next in line for a takeover following the news.
OncoGenex is up over $2 from yesterday's close; Dendreon is up fractionally.
Speculators view these as next in line for a takeover following the news.
OncoGenex is up over $2 from yesterday's close; Dendreon is up fractionally.
You May Also Be Interested In
- Citi (C) rumored to have lost $20M on Facebook (FB) glitches -WSJ
- Morgan Stanley (MS) Shares Pressured on Questionable Facebook (FB) Tactics; Hits Fresh 6-Month Low
- Maastricht Treaty to Blame for Crisis in EU...
Create E-mail Alert Related Categories
Rumors, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
